Literature DB >> 17432143

[Determination of matrine, sophoridine and oxymatrine in Compound Kushen Injection by HPLC].

Juan Tian1, Wei-hao Wang, Hui-min Gao, Zhi-min Wang.   

Abstract

OBJECTIVE: To establish a high performance liquid chromatography (HPLC) method for determination of matrine, sophoridine and oxymatrine in Compound Kushen Injection.
METHOD: Alltima amino column was used with acetonitrile-3% phosphoric acid-ethyl alcohol (80:10:10) as the mobile phase and the detection wavelength was at 220 nm. RESULT: The mean recovery of matrine, sophoridine and oxymatrine in Compound Kushen Injection was 99.51% (RSD 1. 58%), 99.24% (RSD 1.44%) and 100.22% (RSD 1.85%), respectively.
CONCLUSION: The method was simple, rapid, accurate and specific and suitable for quality control of the product.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17432143

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  10 in total

Review 1.  A systematic review and meta-analysis on the use of traditional Chinese medicine compound kushen injection for bone cancer pain.

Authors:  Bao Yanju; Liping Yang; Baojin Hua; Wei Hou; Zhan Shi; Weidong Li; Conghuang Li; Cihui Chen; Rui Liu; Yinggang Qin; Wenliang Lv
Journal:  Support Care Cancer       Date:  2013-11-26       Impact factor: 3.603

2.  Synthesis and biological evaluation of sophoridinol derivatives as a novel family of potential anticancer agents.

Authors:  Chongwen Bi; Caixia Zhang; Yinghong Li; Sheng Tang; Shenggang Wang; Rongguang Shao; Haigen Fu; Feng Su; Danqing Song
Journal:  ACS Med Chem Lett       Date:  2014-09-22       Impact factor: 4.345

Review 3.  Anti-tumor activities of active ingredients in Compound Kushen Injection.

Authors:  Wei Wang; Rong-li You; Wen-jie Qin; Li-na Hai; Ming-jing Fang; Guo-hua Huang; Rui-xia Kang; Ming-hua Li; Yu-feng Qiao; Jian-wei Li; An-ping Li
Journal:  Acta Pharmacol Sin       Date:  2015-05-18       Impact factor: 6.150

4.  Compound Kushen Injection suppresses human breast cancer stem-like cells by down-regulating the canonical Wnt/β-catenin pathway.

Authors:  Weiru Xu; Hongsheng Lin; Ying Zhang; Xinyi Chen; Baojin Hua; Wei Hou; Xin Qi; Yingxia Pei; Xiaoyun Zhu; Zhizheng Zhao; Liangliang Yang
Journal:  J Exp Clin Cancer Res       Date:  2011-10-28

5.  Efficacy of Compound Kushen Injection in Combination with Induction Chemotherapy for Treating Adult Patients Newly Diagnosed with Acute Leukemia.

Authors:  Honglei Tu; Bo Lei; Shan Meng; Hailing Liu; Yongchang Wei; Aili He; Wanggang Zhang; Fuling Zhou
Journal:  Evid Based Complement Alternat Med       Date:  2016-09-21       Impact factor: 2.629

Review 6.  Efficacy and Safety of Compound Kushen Injection on Patients with Advanced Colon Cancer: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Lixiu Yu; Ying Zhou; Yu Yang; Furong Lu; Yeqin Fan
Journal:  Evid Based Complement Alternat Med       Date:  2017-11-12       Impact factor: 2.629

7.  A System Pharmacology Model for Decoding the Synergistic Mechanisms of Compound Kushen Injection in Treating Breast Cancer.

Authors:  Yi Li; Kexin Wang; Yupeng Chen; Jieqi Cai; Xuemei Qin; Aiping Lu; Daogang Guan; Genggeng Qin; Weiguo Chen
Journal:  Front Pharmacol       Date:  2021-11-16       Impact factor: 5.810

8.  Efficacy and safety of traditional Chinese medicine for the treatment of pancreatic cancer: An overview of systematic reviews and meta-analyses.

Authors:  Jing Wang; Qiuyuan Wang; Peitong Zhang; Ruoqi Zhang; Jie He
Journal:  Front Pharmacol       Date:  2022-09-01       Impact factor: 5.988

Review 9.  Efficacy of Compound Kushen Injection in Relieving Cancer-Related Pain: A Systematic Review and Meta-Analysis.

Authors:  Yu-Ming Guo; Yi-Xue Huang; Hong-Hui Shen; Xiu-Xiu Sang; Xiao Ma; Yan-Ling Zhao; Xiao-He Xiao
Journal:  Evid Based Complement Alternat Med       Date:  2015-10-04       Impact factor: 2.629

10.  A multicenter randomized controlled open-label trial to assess the efficacy of compound kushen injection in combination with single-agent chemotherapy in treatment of elderly patients with advanced non-small cell lung cancer: study protocol for a randomized controlled trial.

Authors:  Xue-Qian Wang; Jie Liu; Hong-Sheng Lin; Wei Hou
Journal:  Trials       Date:  2016-03-08       Impact factor: 2.279

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.